Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y9EW
|
|||
| Former ID |
DNAP001683
|
|||
| Drug Name |
Vemurafenib
|
|||
| Synonyms |
PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Melanoma [ICD-11: 2C30] | Approved | [1], [2], [3] | |
| Company |
Daiichi Sankyo group; Genentech
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H18ClF2N3O3S
|
|||
| Canonical SMILES |
CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
|
|||
| InChI |
1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
|
|||
| InChIKey |
GPXBXXGIAQBQNI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 918504-65-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
86450036, 99207986, 99344329, 99436933, 104245715, 123055406, 123393726, 124757131, 125163935, 125240992, 125312523, 125477821, 126731467, 131408691, 131480743, 134213431, 135267495, 135360056, 135611115, 135626717, 135686206, 135686207, 135686222, 135686223, 135727433, 136367377, 136920367, 137241152, 137275900, 138196197, 152258377, 160647214, 160837190, 162011358, 162037528, 162201724, 163098027, 163345507, 163390276, 164041819, 164193918, 164766097, 164834160, 165826640, 170483525, 170498105, 172087033, 172914376, 174531480, 175267423
|
|||
| ChEBI ID |
CHEBI:63637
|
|||
| ADReCS Drug ID | BADD_D02344 | |||
| SuperDrug ATC ID |
L01XE15
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5893). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | ClinicalTrials.gov (NCT01898585) An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.